Andrew Bellinger

Andrew Bellinger is an accomplished medical and scientific professional with extensive leadership experience in biotechnology and healthcare. Currently serving on the Scientific Advisory Board at ReCode Therapeutics since October 2024, Bellinger also co-founded Corner Therapeutics in September 2019, where a role as a board member is held. Previously, Bellinger was the Chief Scientific Officer at Verve Therapeutics from October 2019 to June 2024, and served as Chief Scientific Officer and Co-Founder of Lyndra from June 2015 to September 2019, where leadership in research and development was a key focus. Additional positions include attending cardiologist at Brigham and Women's Hospital from March 2016 to December 2021, a research affiliate at MIT's Langer Lab, and various roles at Brigham and Women’s Hospital and Harvard Medical School during fellowship training. Bellinger holds an MD and PhD from Columbia University Vagelos College of Physicians and Surgeons, as well as degrees in applied mathematics and physics from New York University and Princeton University, respectively.